<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840862</url>
  </required_header>
  <id_info>
    <org_study_id>HS-21-00315</org_study_id>
    <nct_id>NCT04840862</nct_id>
  </id_info>
  <brief_title>Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor</brief_title>
  <official_title>Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in&#xD;
      healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trikafta (Elexacaftor [ELX], Tezacaftor [TEZ], Ivacaftor[IVA]) is contraindicated with&#xD;
      concomitant use of strong inducers as co-administration of rifampin decreased the&#xD;
      area-under-the concentration time curve (AUC) of IVA by 89%, creating a therapeutic challenge&#xD;
      to the treatment of non-tuberculosis mycobacteria (NTM) infection in people with cystic&#xD;
      fibrosis (CF). While rifabutin also induces CYP3A4 activity, its effects appear to be more&#xD;
      moderate when compared with rifampin. Therefore, we hypothesize that rifabutin can be&#xD;
      co-administered with an adjusted dose of ELX/TEZ/IVA in patients being treated for NTM&#xD;
      pulmonary disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single group of subjects will receive a single dose of trikafta (orange tablet) in period 1. After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on day 1 through 17 and a single dose of trikafta (orange tablet) on day 15 in period 2.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h area-under the plasma concentration time curve (AUC) of ELX/TEZ/IVA in the absence and the presence of concomitant rifabutin</measure>
    <time_frame>22 days</time_frame>
    <description>To assess the impact of rifabutin on the AUC of ELX/TEZ/IVA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ELX/TEZ/IVA in the absence and the presence of concomitant rifabutin</measure>
    <time_frame>22 days</time_frame>
    <description>To assess the impact of rifabutin on the Cmax of ELX/TEZ/IVA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Drug Drug Interaction</condition>
  <arm_group>
    <arm_group_label>rifabutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifabutin PO [two 150mg capsules] ; Trikafta PO [one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]</intervention_name>
    <description>Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.</description>
    <arm_group_label>rifabutin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin 300mg</intervention_name>
    <description>After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.</description>
    <arm_group_label>rifabutin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to sign informed consent prior to any study-related activities.&#xD;
&#xD;
          -  Male or female participants between 18 and 65 years of age inclusive.&#xD;
&#xD;
          -  Healthy subjects as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination findings, and clinical laboratory test results&#xD;
&#xD;
          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2, inclusive; and a total body weight &gt;50kg&#xD;
             (110 lbs).&#xD;
&#xD;
          -  Willing to stop using any herbal or natural health products for 2 weeks prior to and&#xD;
             during the study including: Grapefruit, grapefruit juice, St. John's Wort.&#xD;
&#xD;
          -  Participant must use a reliable method of birth control while they are participating&#xD;
             in the study; for instance an intrauterine device (IUD), condom with spermicidal gel&#xD;
             or foam, diaphragm with spermicidal gel or foam, vasectomy, tubal ligation,&#xD;
             hysterectomy or abstinence or female must be post-menopausal for at least one year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects of childbearing potential with positive urine pregnancy test at&#xD;
             screening.&#xD;
&#xD;
          -  Female subjects who are breastfeeding.&#xD;
&#xD;
          -  Use of CYP3A modulators (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin,&#xD;
             azole drugs, telithromycin, clarithromycin, erythromycin)&#xD;
&#xD;
          -  Any significant acute or chronic medical illness that might confound the results of&#xD;
             the study or pose an additional risk in administrating study drugs to the subject, as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  Any condition that could affect drug absorption (eg, gastrectomy, pancreatitis).&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration.&#xD;
&#xD;
          -  Blood donation of approximately 1 pint (500 mL) within 56 days before study drug&#xD;
             administration.&#xD;
&#xD;
          -  Known hypersensitivity to rifamycins&#xD;
&#xD;
          -  Patients with hepatic impairment (Child-Pugh Class B or C) and/or with history of&#xD;
             hepatobiliary disease or liver function test elevations.&#xD;
&#xD;
          -  Renal insufficiency (eGFR &lt; 60 mL/min)&#xD;
&#xD;
          -  History of uveitis and/or current eye or vision problems with the exception of&#xD;
             corrective lenses.&#xD;
&#xD;
          -  Contact lens use during study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adupa P Rao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Keck Medicine of USC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul M. Beringer, PharmD</last_name>
    <phone>323-442-1402</phone>
    <email>beringer@usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul M. Beringer, PharmD</last_name>
      <phone>323-442-1402</phone>
      <email>beringer@usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Beringer</investigator_full_name>
    <investigator_title>Professor of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

